Elaborately Engineering a Self-Indicating Dual-Drug Nanoassembly for Site-Specific Photothermal-Potentiated Thrombus Penetration and Thrombolysis

Overview

Journal Adv Sci (Weinh)

Specialty Biomedical Engineering

Date 2021 Nov 21

PMID 34802198

Citations 16

Authors

Zhiqiang Zhao

Xuanbo Zhang

Hongyuan Zhang

Xinzhu Shan

Meiyu Bai

Zhe Wang

Fujun Yang

Haotian Zhang

Qiming Kan

Bingjun Sun

Jin Sun

Zhonggui He

Cong Luo

Affiliations

Soon will be listed here.

Abstract

Thrombotic cardio-cerebrovascular diseases seriously threaten human health. Currently, conventional thrombolytic treatments are challenged by the low utilization, inferior thrombus penetration, and high off-target bleeding risks of most thrombolytic drugs, resulting in unsatisfactory treatment outcomes. Herein, it is proposed that these challenges can be overcome by precisely integrating the conventional thrombolytic strategy with photothermal therapy. After co-assembly engineering optimization, a fibrin-targeting peptide-decorated nanoassembly of DiR (a photothermal probe) and ticagrelor (TGL, an antiplatelet drug) is prepared for thrombus-homing delivery, abbreviated as FT-DT NPs. The elaborately engineered nanoassembly shows multiple advantages, including simple preparation with high drug co-loading capacity, synchronous delivery of two drugs with long systemic circulation, thrombus-targeted accumulation with self-indicating function, as well as photothermal-potentiated thrombus penetration and thrombolysis with high therapeutic efficacy. As expected, FT-DT NPs not only show bright fluorescence signals in the embolized vessels, but also perform photothermal/antiplatelet synergistic thrombolysis in vivo. This study offers a simple and versatile co-delivery nanoplatform for imaging-guided photothermal/antiplatelet dual-modality thrombolysis.

Citing Articles

Artificial biomarker-based feedback-regulated personalized and precise thrombolysis with lower hemorrhagic risk.

Li L, Tian H, Wu L, Chen N, Zhang Q, Chen L Sci Adv. 2025; 11(3):eadr0377.

PMID: 39823346 PMC: 11740970. DOI: 10.1126/sciadv.adr0377.

Comparative In Vitro Study between Biocompatible Chitosan-Based Magnetic Nanocapsules and Liposome Formulations with Potential Application in Anti-Inflammatory Therapy.

Vochita G, Cadinoiu A, Rata D, Atanase L, Popa M, Mahdieh A Int J Mol Sci. 2024; 25(15).

PMID: 39126023 PMC: 11313677. DOI: 10.3390/ijms25158454.

Dual-mode nanoprobe strategy integrating ultrasound and near-infrared light for targeted and synergistic arterial thrombolysis.

Wang Z, Jiang N, Jiang Z, Wang H, Guo Y, Zhong F J Nanobiotechnology. 2024; 22(1):311.

PMID: 38831332 PMC: 11145811. DOI: 10.1186/s12951-024-02562-w.

Nanotechnology in inflammation: cutting-edge advances in diagnostics, therapeutics and theranostics.

Liu Y, Lin Z, Wang Y, Chen L, Wang Y, Luo C Theranostics. 2024; 14(6):2490-2525.

PMID: 38646646 PMC: 11024862. DOI: 10.7150/thno.91394.

Tea polyphenol-derived nanomedicine for targeted photothermal thrombolysis and inflammation suppression.

Wang H, Tang C, Xiang Y, Zou C, Hu J, Yang G J Nanobiotechnology. 2024; 22(1):146.

PMID: 38566213 PMC: 10988797. DOI: 10.1186/s12951-024-02446-z.

References

Zhou M, Zhang X, Yang Y, Liu Z, Tian B, Jie J . Carrier-free functionalized multidrug nanorods for synergistic cancer therapy. Biomaterials. 2013; 34(35):8960-7. DOI: 10.1016/j.biomaterials.2013.07.080. View

Lewis D, Petersen L, York A, Zablocki K, Joseph L, Kholodovych V . Sugar-based amphiphilic nanoparticles arrest atherosclerosis in vivo. Proc Natl Acad Sci U S A. 2015; 112(9):2693-8. PMC: 4352838. DOI: 10.1073/pnas.1424594112. View

Su M, Dai Q, Chen C, Zeng Y, Chu C, Liu G . Nano-Medicine for Thrombosis: A Precise Diagnosis and Treatment Strategy. Nanomicro Lett. 2021; 12(1):96. PMC: 7770919. DOI: 10.1007/s40820-020-00434-0. View

Zhang F, Liu Y, Lei J, Wang S, Ji X, Liu H . Metal-Organic-Framework-Derived Carbon Nanostructures for Site-Specific Dual-Modality Photothermal/Photodynamic Thrombus Therapy. Adv Sci (Weinh). 2019; 6(17):1901378. PMC: 6724354. DOI: 10.1002/advs.201901378. View

Mackman N . Triggers, targets and treatments for thrombosis. Nature. 2008; 451(7181):914-8. PMC: 2848509. DOI: 10.1038/nature06797. View

Vaezzadeh N, Ni R, Kim P, Weitz J, Gross P . Comparison of the effect of coagulation and platelet function impairments on various mouse bleeding models. Thromb Haemost. 2014; 112(2):412-8. DOI: 10.1160/TH13-11-0919. View

Cheng J, Zhang X, Cheng L, Li G, Zhang L, Ji K . Low-Dose Tissue Plasminogen Activator in Acute Ischemic Stroke: A Systematic Review and Meta-Analysis. J Stroke Cerebrovasc Dis. 2017; 27(2):381-390. DOI: 10.1016/j.jstrokecerebrovasdis.2017.09.014. View

Absar S, Gupta N, Nahar K, Ahsan F . Engineering of plasminogen activators for targeting to thrombus and heightening thrombolytic efficacy. J Thromb Haemost. 2015; 13(9):1545-56. DOI: 10.1111/jth.13033. View

Liu K, Xing R, Zou Q, Ma G, Mohwald H, Yan X . Simple Peptide-Tuned Self-Assembly of Photosensitizers towards Anticancer Photodynamic Therapy. Angew Chem Int Ed Engl. 2016; 55(9):3036-9. DOI: 10.1002/anie.201509810. View

10.

Kim W, Haller C, Dai E, Wang X, Hagemeyer C, Liu D . Targeted antithrombotic protein micelles. Angew Chem Int Ed Engl. 2014; 54(5):1461-5. PMC: 4641307. DOI: 10.1002/anie.201408529. View

11.

Kang C, Gwon S, Song C, Kang P, Park S, Jeon J . Fibrin-Targeted and HO-Responsive Nanoparticles as a Theranostics for Thrombosed Vessels. ACS Nano. 2017; 11(6):6194-6203. DOI: 10.1021/acsnano.7b02308. View

12.

Xu J, Wang X, Yin H, Cao X, Hu Q, Lv W . Sequentially Site-Specific Delivery of Thrombolytics and Neuroprotectant for Enhanced Treatment of Ischemic Stroke. ACS Nano. 2019; 13(8):8577-8588. DOI: 10.1021/acsnano.9b01798. View

13.

Miao L, Guo S, Lin C, Liu Q, Huang L . Nanoformulations for combination or cascade anticancer therapy. Adv Drug Deliv Rev. 2017; 115:3-22. PMC: 5591780. DOI: 10.1016/j.addr.2017.06.003. View

14.

Boeckh-Behrens T, Kleine J, Zimmer C, Neff F, Scheipl F, Pelisek J . Thrombus Histology Suggests Cardioembolic Cause in Cryptogenic Stroke. Stroke. 2016; 47(7):1864-71. DOI: 10.1161/STROKEAHA.116.013105. View

15.

Bala M, Paszek E, Lesniak W, Wloch-Kopec D, Jasinska K, Undas A . Antiplatelet and anticoagulant agents for primary prevention of thrombosis in individuals with antiphospholipid antibodies. Cochrane Database Syst Rev. 2018; 7:CD012534. PMC: 6513409. DOI: 10.1002/14651858.CD012534.pub2. View

16.

Wang Y, Ouyang Y, Liu B, Ma X, Ding R . Platelet activation and antiplatelet therapy in sepsis: A narrative review. Thromb Res. 2018; 166:28-36. DOI: 10.1016/j.thromres.2018.04.007. View

17.

Zhang X, Xiong J, Wang K, Yu H, Sun B, Ye H . Erythrocyte membrane-camouflaged carrier-free nanoassembly of FRET photosensitizer pairs with high therapeutic efficiency and high security for programmed cancer synergistic phototherapy. Bioact Mater. 2021; 6(8):2291-2302. PMC: 7841442. DOI: 10.1016/j.bioactmat.2021.01.004. View

18.

Wang Q, Sun M, Li D, Li C, Luo C, Wang Z . Cytochrome P450 enzyme-mediated auto-enhanced photodynamic cancer therapy of co-nanoassembly between clopidogrel and photosensitizer. Theranostics. 2020; 10(12):5550-5564. PMC: 7196307. DOI: 10.7150/thno.42633. View

19.

Shao J, Abdelghani M, Shen G, Cao S, Williams D, van Hest J . Erythrocyte Membrane Modified Janus Polymeric Motors for Thrombus Therapy. ACS Nano. 2018; 12(5):4877-4885. PMC: 5968433. DOI: 10.1021/acsnano.8b01772. View

20.

Wang K, Yang B, Ye H, Zhang X, Song H, Wang X . Self-Strengthened Oxidation-Responsive Bioactivating Prodrug Nanosystem with Sequential and Synergistically Facilitated Drug Release for Treatment of Breast Cancer. ACS Appl Mater Interfaces. 2019; 11(21):18914-18922. DOI: 10.1021/acsami.9b03056. View